Novavax reported $1.7B in Current Assets for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
Adma Biologics ADMA:US USD 270.4M 46.31M
Agenus AGEN:US USD 213.12M 38.31M
AstraZeneca AZN:LN USD 22.59B 2.37B
Astrazeneca AZN:US USD 22.59B 2.37B
Dynavax Technologies DVAX:US USD 916.98M 15.96M
Geron GERN:US USD 180.25M 41.82M
GlaxoSmithKline GSK:LN GBP 20.77B 520M
Mannkind MNKD:US USD 234.9M 16.52M
Minerva Neurosciences NERV:US USD 40.16M 4.68M
Moderna Inc MRNA:US USD 13.43B 866M
Novartis NVS:US USD 36.91B 44M
Novavax NVAX:US USD 1.7B 56.57M
Pain Therapeutics PTIE:US USD 211.23M 27.95M
Peregrine Pharmaceuticals PPHM:US USD 132.34M 13.6M
Sarepta Therapeutics SRPT:US USD 2.56B 68.07M
Tg Therapeutics TGTX:US USD 168.27M 14.65M